Psyence Biomedical (PBM) has released an update.
Psyence Biomedical Ltd. has received a notification from Nasdaq regarding the company’s non-compliance with the minimum bid price requirement, now facing a 180-day period to regain compliance or potentially face delisting. The biotech firm, specializing in psilocybin-based therapies, remains listed and is actively exploring options to meet Nasdaq’s standards. Investors are watching closely as the company considers measures, including a possible reverse stock split, to address the bid price deficiency.
For further insights into PBM stock, check out TipRanks’ Stock Analysis page.
